Crohn's Disease
Summary
Crohn's disease is a chronic, relapsing inflammatory bowel disease (IBD) that can affect any part of the gastrointestinal tract from mouth to anus, though it most commonly involves the terminal ileum and colon. Unlike ulcerative colitis, Crohn's causes transmural (full-thickness) inflammation, leading to characteristic complications including strictures, fistulae, and abscesses. Inflammation is typically discontinuous ("skip lesions"). The aetiology involves genetic susceptibility, environmental triggers, and immune dysregulation. Treatment aims to induce and maintain remission, prevent complications, and improve quality of life. First-line therapies include corticosteroids for induction and immunomodulators (thiopurines, methotrexate) or biologics (anti-TNF, anti-integrin, anti-IL-12/23) for maintenance.
Key Facts
- Definition: Chronic transmural IBD affecting any part of GI tract
- Age of Onset: Bimodal — 15-30 years and 50-70 years
- Location: Terminal ileum (most common), colon, ileocolonic, upper GI
- Pattern: Skip lesions, transmural inflammation, cobblestoning
- Histology: Non-caseating granulomas (pathognomonic but not always present)
- Complications: Strictures, fistulae, abscesses
- Surgery: Not curative; high recurrence rate
Clinical Pearls
"Crohn's — Mouth to Anus, Skip Lesions, Transmural": Remember the key distinguishing features from UC.
"If Perianal Disease, Think Crohn's": Perianal fistulae and abscesses are common in Crohn's, not UC.
"Anti-TNF Changes the Game": Biologics have transformed Crohn's management, achieving mucosal healing and reducing surgery.
Why This Matters Clinically
Crohn's disease is a lifelong condition causing significant morbidity. Early aggressive treatment can prevent complications and improve long-term outcomes. A multidisciplinary approach involving gastroenterology, surgery, dietetics, and psychology is essential.
Incidence & Prevalence
- Incidence: 5-10 per 100,000 per year (developed countries)
- Prevalence: 100-300 per 100,000
- Trend: Increasing worldwide, especially in developing countries
- Age of Onset: Bimodal — peak 15-30 years; second peak 50-70 years
Demographics
| Factor | Details |
|---|---|
| Age | Bimodal distribution |
| Sex | Slight female predominance |
| Ethnicity | Higher in Caucasians; rising in Asia |
| Smoking | INCREASES risk (unlike UC) |
Risk Factors
| Factor | Effect |
|---|---|
| Genetics | NOD2/CARD15 mutations; family history |
| Smoking | 2x risk; worsens disease |
| Appendicectomy | Possible protective effect |
| Diet | Western diet associated |
| Infections | Possible trigger |
| Antibiotics in childhood | Associated with IBD |
Mechanism
Step 1: Genetic Susceptibility
- NOD2/CARD15, IL23R, ATG16L1 mutations
- Impaired bacterial handling
Step 2: Environmental Trigger
- Smoking, diet, infections, altered microbiome
Step 3: Immune Dysregulation
- Loss of tolerance to gut microbiota
- Th1/Th17 response predominates
- TNF-α, IL-12, IL-23, IFN-γ elevated
Step 4: Transmural Inflammation
- Full-thickness bowel involvement
- Granuloma formation
- Fibrosis, strictures
- Sinus tracts, fistulae
Crohn's vs Ulcerative Colitis
| Feature | Crohn's Disease | Ulcerative Colitis |
|---|---|---|
| Location | Mouth to anus (terminal ileum most common) | Colon only (rectum to proximal) |
| Distribution | Skip lesions | Continuous from rectum |
| Depth | Transmural | Mucosal |
| Histology | Granulomas, transmural inflammation | Crypt abscesses, goblet cell depletion |
| Strictures | Common | Rare |
| Fistulae | Common | Very rare |
| Perianal disease | Common | Rare |
| Surgery | Not curative | Curative (panproctocolectomy) |
| Smoking | Worsens disease | Protective |
Symptoms
Signs
Extra-Intestinal Manifestations
| System | Manifestation |
|---|---|
| Joints | Peripheral arthritis, sacroiliitis, ankylosing spondylitis |
| Skin | Erythema nodosum, pyoderma gangrenosum |
| Eyes | Uveitis, episcleritis |
| Hepatobiliary | PSC, gallstones, fatty liver |
| Oral | Aphthous ulcers |
| Vascular | VTE (increased risk) |
Red Flags
[!CAUTION] Red Flags — Surgical Emergency:
- Bowel obstruction (distension, vomiting, absolute constipation)
- Perforation (acute abdomen, peritonism)
- Intra-abdominal abscess (fever, mass, sepsis)
- Toxic megacolon (rare in Crohn's)
- Massive GI bleeding (rare)
Structured Approach
General:
- Nutritional status (weight, BMI)
- Pallor, clubbing, lymphadenopathy
Abdominal:
- Tenderness (RIF/RLQ common)
- Mass (phlegmon, abscess)
- Scars (previous surgery)
- Stomas
Perianal:
- Fistulae, skin tags
- Abscesses
- Fissures
Extra-Intestinal:
- Joints (peripheral arthritis, spine)
- Skin (erythema nodosum, pyoderma)
- Eyes (red eye → uveitis/episcleritis)
First-Line
| Test | Purpose | Findings |
|---|---|---|
| FBC | Anaemia, thrombocytosis | Anaemia common |
| CRP/ESR | Inflammation | Elevated in active disease |
| Albumin | Nutritional status | Low in severe disease |
| Iron studies, B12, Folate | Deficiencies | Common (malabsorption) |
| LFTs | PSC, drug monitoring | May be abnormal |
| Faecal Calprotectin | Gut inflammation | >250 suggests IBD |
| Stool MCS + C. diff | Exclude infection | Rule out infectious cause |
Imaging
| Modality | Indication |
|---|---|
| MRI Small Bowel | Gold standard for small bowel assessment; strictures, fistulae |
| CT Abdomen/Pelvis | Acute presentation; abscess, perforation |
| MRI Pelvis | Perianal fistulae assessment |
| USS Abdomen | Abscess screening |
Endoscopy
| Procedure | Findings |
|---|---|
| Ileocolonoscopy + biopsies | Skip lesions, cobblestoning, ulcers; histology |
| OGD | Upper GI involvement |
| Capsule Endoscopy | Small bowel if MRI negative and suspicion remains |
Induction of Remission
| Severity | Treatment |
|---|---|
| Mild-Moderate | Budesonide 9mg OD (ileal/right-sided) or Prednisolone 40mg |
| Moderate-Severe | Prednisolone 40mg OD; if fails → anti-TNF |
| Severe Acute | IV Hydrocortisone; consider infliximab rescue |
Maintenance of Remission
| Class | Examples |
|---|---|
| Thiopurines | Azathioprine, Mercaptopurine (check TPMT) |
| Methotrexate | SC/IM weekly |
| Anti-TNF | Infliximab (IV), Adalimumab (SC) |
| Anti-Integrin | Vedolizumab |
| Anti-IL-12/23 | Ustekinumab |
| Anti-IL-23 | Risankizumab |
| JAK Inhibitors | Upadacitinib (emerging) |
Surgery
- Indications: Strictures, fistulae, abscess, perforation, refractory disease
- Limited resection with primary anastomosis
- Not curative (50-70% recurrence)
- Post-op prophylaxis reduces recurrence
Perianal Disease
- MRI pelvis for staging
- Antibiotics (metronidazole + ciprofloxacin)
- EUA + seton insertion
- Anti-TNF (infliximab first-line)
Intestinal
| Complication | Notes |
|---|---|
| Strictures | Obstruction; endoscopic dilatation or surgery |
| Fistulae | Enterocutaneous, enteroenteric, enterovesical, perianal |
| Abscess | Requires drainage |
| Perforation | Surgical emergency |
| Colorectal cancer | Increased risk with colonic involvement |
Nutritional
- Malnutrition, weight loss
- Iron, B12, folate deficiency
- Vitamin D deficiency
- Osteoporosis
Treatment-Related
| Drug | Complications |
|---|---|
| Steroids | Osteoporosis, diabetes, infection, adrenal suppression |
| Thiopurines | Myelosuppression, hepatotoxicity, lymphoma (EBV-associated) |
| Methotrexate | Hepatotoxicity, myelosuppression, ILD |
| Anti-TNF | Serious infections, TB reactivation, demyelination |
Natural History
Crohn's disease is a chronic relapsing-remitting condition. Without treatment, most patients experience flares. Up to 80% require surgery within 20 years of diagnosis. Modern biologic therapy has reduced surgical rates.
Outcomes
| Variable | Outcome |
|---|---|
| Surgery-free rate at 10 years | ~50% (improving with biologics) |
| Recurrence post-surgery | 50-70% within 5-10 years |
| Mortality | Slightly increased (1.5x general population) |
Poor Prognostic Factors
- Perianal disease
- Stricturing or penetrating behaviour
- Young age at onset
- Smoking
- Need for steroids at diagnosis
- Extensive disease
Key Guidelines
-
ECCO Guidelines on Crohn's Disease (2023) — European consensus.
-
NICE NG129: Crohn's Disease (2019) — UK pathway.
Landmark Trials
SONIC Trial (2010) — Combination therapy
- Infliximab + Azathioprine vs monotherapy
- Key finding: Combination superior for remission
- Clinical Impact: Supports combination therapy in anti-TNF-naive patients
UNITI Trials (2016) — Ustekinumab
- Key finding: Ustekinumab effective for anti-TNF failures
- Clinical Impact: IL-12/23 inhibition as alternative mechanism
Evidence Strength
| Intervention | Level | Key Evidence |
|---|---|---|
| Anti-TNF for moderate-severe | 1a | ACCENT, SONIC |
| Thiopurines for maintenance | 1a | Meta-analyses |
| Budesonide for ileal disease | 1a | RCTs |
What is Crohn's Disease?
Crohn's disease is a type of inflammatory bowel disease (IBD). It causes inflammation in your digestive tract, usually the small intestine and/or colon. The inflammation can cause pain, diarrhoea, weight loss, and tiredness.
What causes it?
The exact cause isn't known, but it involves your immune system attacking your gut. Genetics, environment, and gut bacteria all play a role. Smoking makes it worse.
What are the symptoms?
- Diarrhoea (sometimes with blood)
- Abdominal pain, often on the right side
- Weight loss
- Tiredness
- Mouth ulcers
- Problems around the bottom (fistulas, abscesses)
How is it treated?
- Steroids: To calm flare-ups quickly (short-term only)
- Immune-modifying drugs: Azathioprine, methotrexate for long-term control
- Biological medicines: Injections or infusions that target specific parts of the immune system
- Surgery: Sometimes needed for complications like blockages or abscesses
What to expect
- Crohn's is a lifelong condition with flares and remissions
- Most people can live normal lives with treatment
- Regular check-ups and monitoring are important
- You may need to adjust treatment over time
When to seek help
See your doctor or IBD team if:
- Your symptoms get worse
- You have severe abdominal pain or bloating
- You can't keep food or fluids down
- You have a high fever
- You notice new symptoms
Primary Guidelines
- Torres J, Bonovas S, Doherty G, et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment. J Crohns Colitis. 2020;14(1):4-22. PMID: 31711158
Key Trials
-
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease (SONIC). N Engl J Med. 2010;362(15):1383-1395. PMID: 20393175
-
NICE. Crohn's disease: management (NG129). 2019. nice.org.uk/guidance/ng129
Further Resources
- Crohn's & Colitis UK: crohnsandcolitis.org.uk
- ECCO: ecco-ibd.eu
Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate guidelines and specialists for patient care.